聚焦就诊，共话医疗服务新篇 2025年7月21日，美年健康（002044）深圳城市群与深圳市罗湖区人民医院在深圳签署了医疗合作协 议，双方将携手开启深度合作新篇章。此次合作紧密围绕"优势互补、便民惠民、共同发展"的原则，聚 焦转诊、绿通等医疗服务，构建起高效医疗合作桥梁，为客户提供更加精准、高效的医疗服务。 美年健康表示，美年健康一直致力于为民众提供专业的健康管理服务。此次医疗合作，将使双方能够更 好地为客户提供诊疗支持。通过转诊、绿通等相关医疗服务，有需求的客户能够无缝对接到深圳市罗湖 区人民医院，享受到优质的医疗资源。期待双方在更多领域有更深入的合作，为市民提供更多医疗服务 的选择。 深圳市罗湖医院集团副院长、罗湖区人民医院执行院长熊奕强调："作为三甲医院，我们有责任和义务 为区域内居民提供优质的医疗服务。此次合作协议签署之前，我们已经跟美年有过接触，为美年的跨境 客户提供了诊疗服务。相信与美年健康的携手，我们能够更加及时地为患者提供高质量的医疗服务。此 次合作，不仅是双方在优化区域医疗资源配置、提升医疗服务效率领域的积极探索，更是造福更多市民 的创新举措。" 专科协作，精准诊疗再升级 深圳市罗湖区人民医 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [1] Core Views - The company reported strong performance in H1 2025, with revenue reaching 20.64% year-on-year growth and a significant increase in net profit by 101.92% [4][5] - The TIDES business segment showed robust growth, with revenue increasing by 141.6% year-on-year, indicating strong demand and expansion potential [5] - The company has raised its revenue guidance for 2025 from 41.5-43 billion to 42.5-43.5 billion, reflecting positive market conditions and order growth [4] Financial Performance Summary - In H1 2025, the company achieved revenue of 20.799 billion, a 20.64% increase year-on-year, and a net profit of 8.561 billion, up 101.92% [4] - For Q2 2025, revenue was 11.145 billion, showing a 20.37% year-on-year increase and a 15.43% quarter-on-quarter increase [4] - The adjusted Non-IFRS net profit for H1 2025 was 6.31 billion, reflecting a 44.4% year-on-year growth [4] Business Segment Performance - The chemical business segment generated revenue of 16.3 billion in H1 2025, marking a 33.5% increase year-on-year [5] - The TIDES business segment's revenue was approximately 5.03 billion in H1 2025, with a 48.8% increase in orders by the end of June 2025 [5] - The clinical business segment reported a slight decline in revenue, but the overall performance remains stable with a focus on expanding new molecular types [6] Financial Projections - The company expects net profit for 2025-2027 to be 13.407 billion, 15.127 billion, and 17.939 billion respectively, with EPS projected at 4.67, 5.27, and 6.25 [4][8] - The current price-to-earnings ratio (PE) is projected at 21.2, 18.8, and 15.8 for the years 2025, 2026, and 2027 respectively [4][8]

根据药明康德刚刚发布的2025年半年报，报告期内，公司实现营业收入207.99亿元，同比增长20.64%， 其中来自持续经营业务收入同比增长24.24%；归属于上市公司股东的净利润85.6亿元，同比增长 101.92%。 公司同步宣布史上首次中期分红，共计约为10亿元，每10股派发现金红利3.5元。2025年以来，公司现 金分红与回购注销规模达到近70亿元。 公开资料显示，药明康德为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚 洲、欧洲、北美等地均设有运营基地。公司通过独特的"CRDMO"业务模式，不断降低研发门槛，助力 客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研 究、临床前测试和临床试验研究等领域。 半年报显示，随着产能不断提升以更好满足客户需求，截至2025年6月末，公司持续经营业务在手订单 566.9亿元，同比增长37.2%。报告期内，公司持续经营收入204.1亿元，其中来自美国客户收入140.3亿 元，同比增长38.4%；来自欧洲客户收入23.3亿元，同比增长9.2%；来自其他地区客户收入9.0亿元，同 比增长7.6%。 7月31日， ...

创梦天地(01119)再涨8.7%，公司引入Playrix战略投资，或为布局《卡拉比丘》海外发行。 康方生物(09926)涨3%再创新高，依沃西联合方案治疗IO耐药NSCLC三期临床完成首例给药。 智通财经APP获悉，港股恒生指数跌1.07%，跌270点，报24906点；恒生科技指数涨0.34%。港股早盘成 交1672亿港元。 AI概念股走势强劲，近期AI应用迎来多重催化，机构称下半年AI主线具充分投资机遇。美图公司 (01357)涨15.26%；金蝶国际(00268)涨11.70%；汇量科技(01860)涨8.59%；金山云(03896)涨10.14%；快 手-W(01024)涨8.98%；粉笔（02469）涨7.91%。 伟仕佳杰(00856)涨2.88%，公司东南亚业务形成多元布局，机构指其当前估值具备显著上行空间。 三生制药(01530)涨超5%，SSGJ-707出海绑定辉瑞，海外估值提升潜力巨大。 锦欣生殖(01951)盘中涨6.48%，政策红利逐步释放，公司为民营辅助生殖龙头。 铜业股全线走低，特朗普宣布对进口半成品铜等征50%关税，纽铜创下历史最大单日跌幅。紫金矿业 (02899)跌4.93%； ...

Group 1 - Goldman Sachs highlights certain healthcare services and treatments, such as high-end dental implants, cataract surgeries, and specific vaccines, which are not covered by national health insurance or affected by centralized drug procurement, indicating strong potential for continued growth in out-of-pocket medical spending among the "silver-haired" population (aged 50 and above) [1] - Goldman Sachs has upgraded ratings for several stocks expected to benefit from the growth in high-end out-of-pocket treatment projects, including Eye Care (300015.SZ) and Zhifei Biological (300122.SZ) to "Buy," while also rating Purui Eye Care (301239.SZ) and Straumann (SAUHY.US) as "Buy," and upgrading Shengtong Medical (600763.SH) to "Neutral" [1] Group 2 - Goldman Sachs focuses on the "silver-haired" demographic, which possesses strong consumption capability with net assets exceeding 3 million RMB, estimating a total addressable market (TAM) that will grow from 221 billion RMB (31 billion USD) in 2024 to 963 billion RMB (135 billion USD) by 2035, with a compound annual growth rate (CAGR) of 14.3% [2] - The report indicates that in 2024, this demographic will account for only 3% of the total population aged 50 and above but will contribute 5% of the healthcare spending for this group, with expectations that this contribution will rise to 13% by 2035 [2] - Goldman Sachs projects the CAGR for healthcare spending among individuals aged 50 and above with net assets over 3 million RMB during 2024-2035 under baseline, optimistic, and pessimistic scenarios to be 14%, 19%, and 9% respectively [2]

7月30日下午，并购新浪潮·东莞智造跃升新引擎——东莞资本市场2025年高质量发展大会举行，来 自"政产学研金"各界的代表济济一堂，共同探寻并购重组何以成为企业裂变成长、制造业高端跃升的重 要路径。同时，大会也围绕并购方法论、实操要点、协同生态等关键议题展开深入探讨，为东莞上市公 司提供决策参考与战略借鉴。 本次活动由东莞市委金融办指导，东莞市上市公司协会、东莞市投资控股集团有限公司（下称"投控集 团"）主办，东莞证券、东莞银行、东莞信托、东莞科创集团、智数公司、华联期货协办，南方报业传 媒集团东莞分社承办。 在当前资本市场不断改革深化、并购重组持续活跃的背景下，并购不仅是企业扩张、迭代、开拓的关键 路径，更是驱动"东莞智造"向全球价值链高端跃升的核心引擎。东莞，这座底蕴深厚的制造业名城，坐 拥境内外上市企业84家、上市后备企业347家、专精特新企业超3000家，正加速迈向国际科创制造强 市。本次活动以"并购"为核心议题，不仅全面回顾了2024年资本市场发展成果，也通过园区推介、战略 签约、主题演讲、圆桌论坛等多个重磅环节，凝聚各方并购智慧，全面助力"东莞智造"向高端化、智能 化、国际化迈进。 "政产学研金" ...

Core Viewpoint - The Beijing Municipal Government has released measures to enhance the fertility support policy system and promote the establishment of a fertility-friendly society, focusing on improving pediatric healthcare services and resources [1] Group 1: Pediatric Healthcare Improvement - The measures aim to improve the level of children's medical services by ensuring comprehensive coverage of pediatric outpatient services in secondary and higher-level hospitals and maternal and child health hospitals [1] - There is a plan to strengthen the construction of pediatric medical alliances and ensure that each district has at least one member unit and one standardized critical newborn rescue center [1] - The initiative includes dynamic support for the development of key specialties in reproductive health and children's health, with a focus on performance-based salary distribution favoring pediatric fields [1] Group 2: Community and Resource Development - The measures emphasize the expansion and equitable distribution of quality pediatric medical resources, reinforcing the network of basic children's healthcare services [1] - There is a commitment to optimize health management services for children under six years old and to promote suitable medical techniques that align with the physiological characteristics of infants and young children [1] - The government encourages the research and development of pediatric medications to diversify the types, forms, and specifications of drugs suitable for children [1] Group 3: Financial Support and Insurance - Strengthening the financial protection for children's medical expenses is a priority, with plans to include eligible pediatric medications in the medical insurance payment scope [1] - Medical institutions with pediatric diagnosis and treatment capabilities will be allowed to adjust the use of in-hospital preparations from children's specialty hospitals [1]

国元证券指出，医保局座谈会明确了支持医疗器械行业"反内卷"、开放出海、差异化创新等原则，利好 行业高质量发展。集采价格有望进一步温和，促进企业盈利企稳提升；政策将激发医疗器械企业创新研 发积极性，新产品推出有望打开成长空间并加速国产替代；随着研发能力增强，政策助力中国创新药械 全球化发展，为企业开拓全球市场。医药生物行业方面，创新药进入成果兑现阶段，研发进展催化较 多，且不受贸易战影响，将持续作为投资主线；出海领域在新兴市场布局的企业发展潜力大。不同医药 领域的集采持续推进，部分细分赛道影响已出清，未来有望迎来新成长。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅可达20%。该指数从创业 板市场中选取涉及生物医药、医疗器械等业务的上市公司证券作为指数样本，成分股覆盖创新药研发、 生物技术及医疗服务等行业，以反映创业板医疗健康相关上市公司证券的整体表现。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的 ...

同样来自基层一线、2024年9月被分配到下姜村工作的王志文表示："乡村的诊室或许不大，但装得 下我们的医学理想。" 两位大学生村医对基层服务的深切体会，折射出新一代村医渴望突破瓶颈、守护乡民的心声。 乡村医生是农村医疗卫生服务的网底，高校毕业生是充实优化乡村医生队伍的关键力量。为此，浙 江省精准解题—— 7月30日，浙江省大学生乡村医生赋能计划首期培训班在浙大二院启动，127名扎根乡村的年轻医者 踏上为期三年的能力进阶之路。 湖州市善琏镇"95后"中医师莫诚杰是浙江首批中医定向生，自2018年毕业后便坚守在善琏镇卫生 院。他坦言，基层医疗面临"设备缺、人员少、任务重"等困境，一名全科医生需应对村民"从头到脚"的 疾病，更要关注其心理问题与生活难题。服务区域内，60岁以上老人占比超40%，子女外出导致的"就 医难"使小病拖成大病的风险陡增。诊室内挂满的锦旗是无声的褒奖，面对乡亲们沉甸甸的信赖，莫诚 杰心里满是提升医疗能力、守护"治未病"防线的迫切渴望。 日前，根据《浙江省县域医共体医疗卫生人才"县乡村一体化"管理改革试点方案》《浙江省新时代 大学生乡村医生队伍建设赋能计划实施方案》等文件精神，浙江省卫生健康委研 ...

截至2024年年报，锦欣生殖营业总收入28.12亿元、净利润2.83亿元。 锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提 供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名 第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第 一。 7月31日，锦欣生殖(01951)盘中上涨5.56%，截至09:30，报3.42元/股，成交4288.43万元。 本文源自：金融界 作者：行情君 ...